| Sep 10 |
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
|
| Sep 5 |
Perspective gets FDA fast track status for radiopharmaceutical VMT01
|
| Sep 5 |
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
|
| Aug 28 |
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
|
| Aug 13 |
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
|
| Aug 12 |
Earnings Summary: Perspective Therapeutics posts mixed Q2, expects sufficient funding till mid-2026
|
| Aug 12 |
Perspective Therapeutics: Q2 Earnings Snapshot
|
| Aug 12 |
Perspective Therapeutics GAAP EPS of -$0.18 misses by $0.05, revenue of $0.53M beats by $0.39M
|
| Aug 12 |
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
|
| Aug 11 |
Perspective Therapeutics Q2 Earnings Preview
|
